UA78977C2 - Drug comprising amino acids and riboflavin for reducing toxicity of anticancer chemotherapy - Google Patents
Drug comprising amino acids and riboflavin for reducing toxicity of anticancer chemotherapy Download PDFInfo
- Publication number
- UA78977C2 UA78977C2 UA20040605059A UA20040605059A UA78977C2 UA 78977 C2 UA78977 C2 UA 78977C2 UA 20040605059 A UA20040605059 A UA 20040605059A UA 20040605059 A UA20040605059 A UA 20040605059A UA 78977 C2 UA78977 C2 UA 78977C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cancer
- amino acids
- patients
- administration
- chemotherapy
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract description 40
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title abstract description 38
- 238000002512 chemotherapy Methods 0.000 title abstract description 32
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title abstract description 19
- 235000019192 riboflavin Nutrition 0.000 title abstract description 19
- 229960002477 riboflavin Drugs 0.000 title abstract description 19
- 239000002151 riboflavin Substances 0.000 title abstract description 19
- 229940079593 drug Drugs 0.000 title description 19
- 239000003814 drug Substances 0.000 title description 19
- 231100000419 toxicity Toxicity 0.000 title description 4
- 230000001988 toxicity Effects 0.000 title description 4
- 230000001093 anti-cancer Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 58
- 201000011510 cancer Diseases 0.000 abstract description 47
- 238000000034 method Methods 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 19
- 150000003839 salts Chemical class 0.000 abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 230000004143 urea cycle Effects 0.000 abstract description 10
- 239000012636 effector Substances 0.000 abstract description 9
- 239000003085 diluting agent Substances 0.000 abstract description 5
- 231100000433 cytotoxic Toxicity 0.000 abstract description 4
- 230000001472 cytotoxic effect Effects 0.000 abstract description 4
- 239000000969 carrier Substances 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 235000020776 essential amino acid Nutrition 0.000 abstract 1
- 239000003797 essential amino acid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 39
- 239000000243 solution Substances 0.000 description 39
- 239000007924 injection Substances 0.000 description 38
- 238000002347 injection Methods 0.000 description 38
- 238000011282 treatment Methods 0.000 description 34
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 239000004475 Arginine Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 15
- 238000001802 infusion Methods 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 229960003104 ornithine Drugs 0.000 description 13
- 239000004471 Glycine Substances 0.000 description 12
- 206010016256 fatigue Diseases 0.000 description 12
- 229960003080 taurine Drugs 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 11
- 239000004474 valine Substances 0.000 description 11
- 239000004473 Threonine Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 230000000771 oncological effect Effects 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 235000003715 nutritional status Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 239000008174 sterile solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- -1 for example Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 229940087620 aromasin Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 208000030212 nutrition disease Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000024335 physical disease Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000023747 urothelial carcinoma Diseases 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HEQRYQONNHFDHG-TZSSRYMLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 HEQRYQONNHFDHG-TZSSRYMLSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- ZHOBCKNWWUIWLU-KIYNQFGBSA-N NC(C(=O)O)C[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2=CN=C3N=C(N)NC(=O)C3=N2)C=C1 Chemical compound NC(C(=O)O)C[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2=CN=C3N=C(N)NC(=O)C3=N2)C=C1 ZHOBCKNWWUIWLU-KIYNQFGBSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 241000953555 Theama Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- BIRDWDHHBHSULZ-UHFFFAOYSA-N n-(2,6-dioxopiperidin-1-yl)-2-phenylacetamide Chemical compound O=C1CCCC(=O)N1NC(=O)CC1=CC=CC=C1 BIRDWDHHBHSULZ-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000004577 thatch Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/995,010 US20030105104A1 (en) | 2001-11-27 | 2001-11-27 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| PCT/US2002/037354 WO2003045372A1 (en) | 2001-11-27 | 2002-11-21 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA78977C2 true UA78977C2 (en) | 2007-05-10 |
Family
ID=25541300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040605059A UA78977C2 (en) | 2001-11-27 | 2002-11-21 | Drug comprising amino acids and riboflavin for reducing toxicity of anticancer chemotherapy |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20030105104A1 (ro) |
| EP (1) | EP1450781B1 (ro) |
| JP (1) | JP4614660B2 (ro) |
| KR (1) | KR100953483B1 (ro) |
| CN (1) | CN100358527C (ro) |
| AT (1) | ATE330595T1 (ro) |
| BR (1) | BR0214430A (ro) |
| CA (1) | CA2468133C (ro) |
| DE (1) | DE60212693T2 (ro) |
| EA (1) | EA009516B1 (ro) |
| HU (1) | HU230986B1 (ro) |
| IL (2) | IL162141A0 (ro) |
| MX (1) | MXPA04004994A (ro) |
| NO (1) | NO332858B1 (ro) |
| NZ (1) | NZ532833A (ro) |
| PL (1) | PL353656A1 (ro) |
| RO (1) | RO121173B1 (ro) |
| SI (1) | SI21542A (ro) |
| UA (1) | UA78977C2 (ro) |
| WO (1) | WO2003045372A1 (ro) |
| ZA (1) | ZA200404115B (ro) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100413866C (zh) * | 2002-08-02 | 2008-08-27 | 中国人民解放军军事医学科学院放射医学研究所 | 核黄素衍生物及其制备方法与应用 |
| US20060035981A1 (en) * | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| US20070248693A1 (en) * | 2003-08-02 | 2007-10-25 | Elizabeth Mazzio | Nutraceutical composition and method of use for treatment / prevention of cancer |
| ES2537974T3 (es) * | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática |
| JP5033802B2 (ja) * | 2005-09-19 | 2012-09-26 | オムニビジョン テクノロジーズ， インコーポレイテッド | タスク型画像化システム |
| CA2645833C (en) * | 2006-03-15 | 2014-12-30 | Suntory Limited | Compositions containing riboflavin and sesamin-class compounds |
| WO2008050836A1 (fr) * | 2006-10-25 | 2008-05-02 | Ajinomoto Co., Inc. | Agent destiné à l'amélioration des effets secondaires d'un agent chimiothérapeutique |
| WO2008105384A1 (ja) * | 2007-02-26 | 2008-09-04 | Kyowa Hakko Bio Co., Ltd. | シトルリン含有錠剤 |
| JP5591533B2 (ja) | 2007-03-15 | 2014-09-17 | サントリーホールディングス株式会社 | 抗疲労剤 |
| WO2010011927A1 (en) | 2008-07-25 | 2010-01-28 | Noventis, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| CA2737619A1 (en) | 2008-09-19 | 2010-03-25 | Nestec S.A. | Nutritional support of the immune system during anti-cancer treatment |
| AU2014200578B2 (en) * | 2008-09-19 | 2016-08-11 | Société des Produits Nestlé S.A. | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| PT3686183T (pt) | 2009-04-03 | 2022-10-03 | Ocera Therapeutics Inc | Fenilacetato de l-ornitina e métodos de preparação do mesmo |
| US20120157526A1 (en) | 2009-06-08 | 2012-06-21 | Ucl Business Plc | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
| US8449512B2 (en) | 2010-04-09 | 2013-05-28 | Davinci Biomedical Research Products Inc. | Stoma stabilitating device and method |
| EP2397458A1 (en) * | 2010-06-21 | 2011-12-21 | Lunamed AG | Organic salts and co-crystals of phenylbutyric acid |
| JP2013532661A (ja) | 2010-07-22 | 2013-08-19 | リベン ファーマシューティカルズ インコーポレイテッド | 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法 |
| KR102069790B1 (ko) * | 2010-09-24 | 2020-01-23 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 위장 기능을 증진시키기 위한 물질 및 방법 |
| KR101888215B1 (ko) | 2010-10-06 | 2018-09-20 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조 방법 |
| TWI489981B (zh) * | 2010-12-10 | 2015-07-01 | 柏萊迪健康科學有限責任公司 | 使用茉莉酸治療膀胱功能障礙 |
| TWI551288B (zh) * | 2011-02-17 | 2016-10-01 | Ea Pharma Co Ltd | Antimicrobial activity enhancer for chemotherapeutic agents |
| ES2630306T3 (es) * | 2011-07-07 | 2017-08-21 | Research Cancer Institute Of America | Sistemas, métodos, y formulaciones para tratar el cáncer |
| CN110522744B (zh) | 2013-03-11 | 2023-04-07 | 佛罗里达大学研究基金会有限公司 | 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法 |
| MX2016006006A (es) * | 2013-11-08 | 2016-07-18 | Legacy Healthcare Ltd | Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer. |
| JP6598425B2 (ja) * | 2014-02-27 | 2019-10-30 | 花王株式会社 | 疲労の評価方法 |
| NZ732632A (en) | 2014-11-24 | 2021-07-30 | Ucl Business Ltd | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3337473A4 (en) | 2015-08-18 | 2019-04-17 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| CN105495582A (zh) * | 2015-12-11 | 2016-04-20 | 北京康比特体育科技股份有限公司 | 一款抗疲劳、促恢复的保健食品氨基酸组合物 |
| EP3621947A4 (en) | 2017-05-11 | 2021-03-10 | Ocera Therapeutics, Inc. | L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| JPS58126767A (ja) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | 肝臓病患者用栄養組成物 |
| DE3672950D1 (de) * | 1985-10-23 | 1990-08-30 | Mulli Kurt Nachf Gmbh | Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung. |
| US5045468A (en) * | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
| EP0421309B2 (en) * | 1989-10-02 | 2001-08-16 | Novartis Nutrition AG | Protein hydrolysates |
| US5292773A (en) * | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
| ES2173109T3 (es) * | 1992-12-23 | 2002-10-16 | Abbott Lab | Alimentos de unso medico destinados parael sostenimiento nutricional de recien nacidos/de bebes que padecen enfermedades metabolicas. |
| US5571783A (en) * | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| FR2705765B1 (fr) * | 1993-04-29 | 1995-08-18 | Eurofours Sa | Porte de four. |
| US5547927A (en) * | 1993-05-28 | 1996-08-20 | Abbott Laboratories | Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy |
| NZ248605A (en) * | 1993-05-28 | 1994-12-22 | Abbott Lab | Enteral nutritional product comprising protein and fat |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| US5656608B1 (en) * | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
| US5728678A (en) * | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
| US5776913A (en) * | 1995-10-10 | 1998-07-07 | Colgate Palmolive Company | Therapeutic diet for metabolic abnormalities found in animals with lymphoma |
| ATE310505T1 (de) * | 1996-05-14 | 2005-12-15 | Stanislaw R Burzynski | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
| US5817927A (en) * | 1997-04-11 | 1998-10-06 | Betzdearborn Inc. | Method and apparatus for monitoring water process equipment |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| ES2205646T3 (es) | 1999-06-26 | 2004-05-01 | B. Braun Melsungen Ag | Solucion acuosa para la nutricion parenteral. |
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| US6377094B1 (en) * | 2002-03-25 | 2002-04-23 | Oak Technology, Inc. | Arbitrary waveform synthesizer using a free-running ring oscillator |
-
2001
- 2001-11-27 US US09/995,010 patent/US20030105104A1/en not_active Abandoned
-
2002
- 2002-04-26 PL PL02353656A patent/PL353656A1/xx not_active Application Discontinuation
- 2002-11-21 EA EA200400737A patent/EA009516B1/ru not_active IP Right Cessation
- 2002-11-21 CN CNB028236068A patent/CN100358527C/zh not_active Expired - Fee Related
- 2002-11-21 MX MXPA04004994A patent/MXPA04004994A/es active IP Right Grant
- 2002-11-21 NZ NZ532833A patent/NZ532833A/en not_active IP Right Cessation
- 2002-11-21 AT AT02789801T patent/ATE330595T1/de not_active IP Right Cessation
- 2002-11-21 DE DE60212693T patent/DE60212693T2/de not_active Expired - Lifetime
- 2002-11-21 KR KR1020047007754A patent/KR100953483B1/ko active IP Right Grant
- 2002-11-21 EP EP02789801A patent/EP1450781B1/en not_active Expired - Lifetime
- 2002-11-21 IL IL16214102A patent/IL162141A0/xx unknown
- 2002-11-21 RO ROA200400481A patent/RO121173B1/ro unknown
- 2002-11-21 CA CA2468133A patent/CA2468133C/en not_active Expired - Fee Related
- 2002-11-21 UA UA20040605059A patent/UA78977C2/uk unknown
- 2002-11-21 BR BR0214430-1A patent/BR0214430A/pt not_active Application Discontinuation
- 2002-11-21 JP JP2003546874A patent/JP4614660B2/ja not_active Expired - Fee Related
- 2002-11-21 SI SI200220037A patent/SI21542A/sl not_active IP Right Cessation
- 2002-11-21 WO PCT/US2002/037354 patent/WO2003045372A1/en active IP Right Grant
- 2002-11-21 HU HU0402240A patent/HU230986B1/hu not_active IP Right Cessation
-
2004
- 2004-05-24 IL IL162141A patent/IL162141A/en not_active IP Right Cessation
- 2004-05-26 ZA ZA2004/04115A patent/ZA200404115B/en unknown
- 2004-06-07 NO NO20042364A patent/NO332858B1/no not_active IP Right Cessation
-
2005
- 2005-04-18 US US11/108,277 patent/US7427619B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA78977C2 (en) | Drug comprising amino acids and riboflavin for reducing toxicity of anticancer chemotherapy | |
| CN103120655B (zh) | 用于改善/预防类固醇治疗中的不利副作用的组合物 | |
| CN105120876A (zh) | 癌症的治疗 | |
| US6083931A (en) | Method of inhibiting cancer metastasis | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| AU2020248270B2 (en) | Chiauranib for treatment of small cell lung cancer | |
| Adams et al. | The management of multiple myeloma | |
| Block et al. | Vitamin C in alternative cancer treatment: historical background | |
| AU2002352843B2 (en) | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | |
| AU2016311704B2 (en) | Use of dihydroxyacetone in preparation of anti-cancer medicaments | |
| EP3965734A1 (en) | Method for increasing cancer patient's haemoglobin level | |
| CN114748630B (zh) | 具有改善功效的铂类抗癌药物组合物及其用途 | |
| CN117357534A (zh) | 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途 | |
| EP3527211A1 (en) | Pharmaceutical composition for treatment or remission of chronic myelogenous leukemia | |
| CN105833253A (zh) | 一种含有苯乙双胍的复方降糖制剂及其制备方法 | |
| JPS59184124A (ja) | 腎不全、糖尿病及び糖尿病性腎症におけるエネルギー代謝改善剤 | |
| JPS59501545A (ja) | 抗腫瘍医薬調剤 |